These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

135 related items for PubMed ID: 9636513

  • 1. Influence of hepatitis C virus infection on FK 506 blood levels in renal transplant patients.
    Manzanares C, Moreno M, Castellanos F, Cubas A, Herrero JC, Morales-Ruiz E, Segura J, Andres A, Morales JM.
    Transplant Proc; 1998 Jun; 30(4):1264-5. PubMed ID: 9636513
    [No Abstract] [Full Text] [Related]

  • 2. Conversion of renal transplant immunosuppression from tacrolimus (FK 506) to cyclosporine: a single center experience.
    Ichikura H, Tanabe K, Tokumoto T, Shimuzu T, Ishikawa N, Harano M, Inui M, Manu M, Ito S, Shimmura H, Okuda H, Yagisawa T, Fuchinoue S, Toma H.
    Transplant Proc; 2000 Nov; 32(7):1733-5. PubMed ID: 11119911
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Therapeutic drug monitoring of tacrolimus in kidney transplantation: 9-month follow-up.
    Brunet M, Torregrosa JV, Oppenheimer F, Corbella J.
    Transplant Proc; 1998 Dec; 30(8):4068-9. PubMed ID: 9865298
    [No Abstract] [Full Text] [Related]

  • 10. Low-dose tacrolimus (FK 506)-based immunosuppressive protocol in living donor renal transplantation.
    Kokado Y, Takahara S, Kyo M, Ichimaru N, Toki K, Wang JD, Okuyama A.
    Transplant Proc; 1999 Dec; 31(1-2):1151-4. PubMed ID: 10083515
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Conversion from Neoral (cyclosporine) to tacrolimus of kidney transplant recipients for gingival hyperplasia or hypertrichosis.
    Busque S, Demers P, St-Louis G, Boily JG, Tousignant J, Lemieux F, Smeesters C, Corman J, Daloze P.
    Transplant Proc; 1998 Jun; 30(4):1247-8. PubMed ID: 9636507
    [No Abstract] [Full Text] [Related]

  • 13. Clinical relevance of monitoring tacrolimus: comparison of microparticle enzyme immunoassay, enzyme-linked immunosorbent assay, and liquid chromatography mass spectrometry in renal transplant recipients converted from cyclosporine to tacrolimus.
    Braun F, Lorf T, Schütz E, Christians U, Grupp C, Sattler B, Canelo R, Sewing KF, Armstrong VW, Oellerich M, Ringe B.
    Transplant Proc; 1996 Dec; 28(6):3175-6. PubMed ID: 8962231
    [No Abstract] [Full Text] [Related]

  • 14. Factors affecting the pharmacokinetics of tacrolimus in the first year after renal transplantation. European Tacrolimus Multicentre Renal Study Group.
    Undre NA, Schäfer A.
    Transplant Proc; 1998 Jun; 30(4):1261-3. PubMed ID: 9636512
    [No Abstract] [Full Text] [Related]

  • 15. FK506 rescue therapy for acute renal allograft rejection.
    Goh BL, Morad Z, Cheah PL, Chua CT, Tan SY.
    Transplant Proc; 1998 Nov; 30(7):3592-3. PubMed ID: 9838574
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.